Cargando…
In vivo effects of rosiglitazone in a human neuroblastoma xenograft
BACKGROUND: Neuroblastoma (NB) is the most common extra-cranial solid tumour in infants. Unfortunately, most children present with advanced disease and have a poor prognosis. There is in vitro evidence that the peroxisome proliferator-activated receptor γ (PPARγ) might be a target for pharmacologica...
Autores principales: | Cellai, I, Petrangolini, G, Tortoreto, M, Pratesi, G, Luciani, P, Deledda, C, Benvenuti, S, Ricordati, C, Gelmini, S, Ceni, E, Galli, A, Balzi, M, Faraoni, P, Serio, M, Peri, A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837558/ https://www.ncbi.nlm.nih.gov/pubmed/20068562 http://dx.doi.org/10.1038/sj.bjc.6605506 |
Ejemplares similares
-
Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
por: Cellai, I, et al.
Publicado: (2006) -
Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft
por: Petrangolini, G, et al.
Publicado: (2004) -
Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-γ
por: Ribatti, D, et al.
Publicado: (2006) -
PPARγ in Neuroblastoma
por: Peri, Alessandro, et al.
Publicado: (2008) -
Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)